PROM1 and neoplasm: Furthermore, we have investigated the effect of CD133 promoter methylation status on patient outcome by stratifying with tumor grades, corresponding PFS and OS data were assessed in LGG (low grade glioma, WHO 2) and HGG (high grade glioma, WHO 3 or 4) patients.